Pfizergan Would Have Challenged Novartis For 2015 Approvals Crown
Executive Summary
Novartis had the most new molecular entity approvals in 2015 with four, all developed in house; next in line is Allergan, with three approvals that stem from acquisitions and licensing.
You may also be interested in...
No Dominant Sponsors In US FDA's 2016 Novel Approvals Class
No company received more than two approvals among the 28 novel agents approved in 2016 by US FDA's drug and biologics centers combined.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.